Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379501 | 1.00 | MTNR1A (0.51) | MTNR1AALDH1A1KDM4EMTNR1BATM | |
| SCHEMBL1504120 | 0.82 | HTT (0.39) | MTNR1AHTTPDE5A | |
| SCHEMBL3861339 | 0.82 | HTT (0.39) | MTNR1AHTTPDE5A | |
| SCHEMBL64217 | 0.82 | HTT (0.39) | MTNR1AHTTPDE5A | |
| SCHEMBL20464506 | 0.79 | ALDH1A1 (0.39) | MTNR1AALDH1A1HTT | |
| SCHEMBL2936974 | 0.78 | GAA (0.53) | CA1CA2 | |
| SCHEMBL3307631 | 0.78 | GAA (0.53) | CA1CA2 | |
| SCHEMBL9846492 | 0.78 | GAA (0.53) | CA1CA2 | |
| SCHEMBL1333586 | 0.74 | — | — | |
| SCHEMBL16281184 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562009-B2 | Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | claimed |
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | claimed |
| JP-4796620-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-7485731-B2 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | claimed |
| EP-1861362-B1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | claimed |
| EP-1861362-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097197-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | claimed |
| US-20060211869-A1 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | US | claimed |
| US-9562009-B2 | Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2016177686-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-7485731-B2 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1861362-B1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1861362-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097197-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211869-A1 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | NANS, PFAS, ALDH18A1 | MTNR1A 3970/4885ALDH1A1 177/4885KDM4E 716/4885 |
| US-20060211869-A1 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | CYP4B1, CYP3A4, IL4 | MTNR1A 3392/4885ALDH1A1 1354/4885KDM4E 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.